Mutations in genes involved in regulation of cell proliferation (Fms-like tyrosine kinase 3, c-KIT, RAS etc.,) and apoptosis (nucleophosmin, p53 etc) are used as a prognostic factor of clinical outcome in AML. This evidence concerns the gene TP53 and acute myeloid leukemia.